Molecular Partners AG annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Molecular Partners AG R&D Spending Growth & History (MOLN)
Molecular Partners AG's r&d spending was CHF40.2M for fiscal 2025.
View full Molecular Partners AG company overviewMolecular Partners AG annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | CHF40.2M | −CHF8.4M | −17.30% |
| 2024 | 2024-12-31 | CHF48.6M | −CHF180,000 | −0.37% |
| 2023 | 2023-12-31 | CHF48.8M | −CHF2.0M | −3.87% |
| 2022 | 2022-12-31 | CHF50.7M | −CHF5.0M | −8.92% |
| 2021 | 2021-12-31 | CHF55.7M | −CHF357,000 | −0.64% |
| 2020 | 2020-12-31 | CHF56.1M | CHF12.6M | +28.91% |
| 2019 | 2019-12-31 | CHF43.5M | — | — |
Molecular Partners AG quarterly r&d spending
Q2.22
Q2.23
Q2.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | CHF9.6M | −CHF1.1M | −10.24% |
| Q1 2026 | 2026-03-31 | CHF9.4M | −CHF2.5M | −20.77% |
| Q4 2025 | 2025-12-31 | CHF9.2M | — | — |
| Q3 2025 | 2025-09-30 | CHF8.3M | — | — |
| Q2 2025 | 2025-06-30 | CHF10.7M | −CHF2.4M | −18.19% |
| Q1 2025 | 2025-03-31 | CHF11.9M | — | — |
| Q2 2024 | 2024-06-30 | CHF13.1M | CHF1.5M | +12.51% |
| Q2 2023 | 2023-06-30 | CHF11.6M | −CHF939,000 | −7.47% |
| Q2 2022 | 2022-06-30 | CHF12.6M | — | — |
Molecular Partners AG r&d spending trends
Over the last five fiscal years, Molecular Partners AG's r&d spending decreased from CHF56.1M to CHF40.2M, a change of −CHF15.9M. The latest reported quarter, Q2 2026, shows CHF9.6M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Molecular Partners AG source filings ↗